SOUTH SAN FRANCISCO, Calif., March 27 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul R. Rodriguez, the company's executive vice president and chief operating officer, is scheduled to present a company overview at the 8th Annual Fortis Biotech Conference in London, England on Thursday, April 3 at 2:30 p.m. GMT.
About Rigel (http://www.rigel.com/) Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer. http://www.newscom.com/cgi-bin/prnh/20030226/RIGLLOGO http://photoarchive.ap.org/ DATASOURCE: Rigel Pharmaceuticals, Inc.
CONTACT: Ryan Maynard of Rigel Pharmaceuticals, Inc., +1-650-624-1284, Web site: http://www.rigel.com/
|